24
Oct
2019

Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Candid Goes Public, Uniqure’s FDA Dispute, & Moderna’s Big Legal Bill
Gilead Acquires Arcellx, Alkermes Passes the Torch, Beam Borrows Big
FDA Flip-Flops on Flu Vaccine, Compass Passes Phase 3, & J&J Bets on Pennsylvania
Eikon Goes Public, Generate Biomedicines Teed Up, & Sante Reloads